Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b/3 study of BPS-804 for the treatmetn of osteogenesis imperfecta in paediatric patients.

Trial Profile

A phase 2b/3 study of BPS-804 for the treatmetn of osteogenesis imperfecta in paediatric patients.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Setrusumab (Primary)
  • Indications Osteogenesis imperfecta
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2018 According to a Mereo BioPharma media release, study design has been approved by the EMA.
    • 23 Mar 2018 According to a Mereo BioPharma media release, the company intends to commence this Phase 2b/3 clinical trial in the second half of 2018.
    • 14 Dec 2017 According to a Mereo BioPharma media release, company has recently submitted its Paediatric Investigation Plan (PIP) for BPS-804 to the Paediatric committee of the European Medicines Agency (PDCO) to initiate this clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top